Bernstein Maintains Market Perform on Revolution Medicines, Raises Price Target to $179
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perform and raises the price target from $151 to $179.
Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perform and raises the price target from $151 to $179.